Abstract

A thorough family history evaluation remains a critical tool that helps identify those patients who are at risk for hereditary cancer. The American College of Obstetricians and Gynecologists (ACOG) recommends that all women receive a family history evaluation to screen for inherited risk, and that this information be regularly updated. Patients with an abnormal cancer family history need additional follow-up that may include hereditary cancer testing. Multigene panel testing provides comprehensive profiling for hereditary cancer patients by identifying more health risks than single genome testing. If hereditary cancer is established, patients should be counseled about management options, including increased surveillance, chemoprevention, and/or surgery. Establishing workflow protocols may help clinicians integrate hereditary cancer risk assessment into their practice.

This CME activity is available through the Website of the American Journal of Obstetrics & Gynecology ( www.ajog.org ). Click on the CME button in the navigation bar for full access. Or access: http://www.elseviercme.com/ajog/546

Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

Funding: This CME activity has been supported by an independent educational grant from Myriad Genetics.

Authorship: All authors had access to all data in preparation of this multimedia activity.

ACKNOWLEDGMENT: This enduring material has been reviewed and accepted by the American Journal of Obstetrics & Gynecology.

Jointly provided by Postgraduate Institute for Medicine and Miller Medical Communications.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Miller Medical Communications, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity

Richard E. Frieder, MD is a consultant/advisor for Myriad Genetics, Phenogen Sciences; is on speaker’s bureau for Myriad Genetics, Phenogen Sciences.

Shari Goldman Snow, MD is on speaker’s bureau for Myriad Genetics.

Marra S. Francis, MD, FACOG is a consultant/advisor for Myriad Genetics; is on speakers bureau for Myriad Genetics.

Burton S. Brodsky, MD is on speaker’s bureau for Myriad Genetics, and Intuitive Surgical.

Planners, Managers, Reviewers: The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Schultz, RN, MSN, CCMEP; and Lyerka Miller, PhD hereby state that they or their spouse/life partner did not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.